Sign in
Taking people in United StatesPhase 1/2

Tests CR-002 in adults with advanced solid tumors

Tests the safety of CR-002 in adults with several advanced solid cancers.

Key facts

Who runs it
Crescent Biopharma, Inc.
Where
Austin, Dallas, and Fairfax, United StatesSee the 3 sites
Registry title
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
219 people, planned
Started
21 Oct 2026
Expected to end
Jan 2029
Type of study
Interventional, 2 groups
Treatments tested
  • CR-002
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or spreading solid tumors of certain types who have run out of standard treatment options.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Locally advanced or metastatic cancer of one of these types: head and neck squamous cell, gastric/GEJ, biliary tract, esophageal squamous cell, ovarian, endometrial, cervical, or non-small cell lung. The disease must be measurable by RECIST v1.1. The cancer is getting worse on, cannot be treated with, or has no available local standard treatment.
Earlier treatment
Must have progressed on, not tolerated, or be unable to receive local standard treatments. Must not have had an antibody-drug conjugate with a topoisomerase I inhibitor payload.

Main reasons for not taking part

  • Another cancer within the past 3 years
  • Active cancer spread to the brain or spinal cord (CNS metastases)
  • Earlier treatment with an antibody-drug conjugate with a topoisomerase I inhibitor payload
  • Not recovered from recent major surgery, or ongoing serious side effects from earlier treatment
  • Known sensitivity to any component of CR-002

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Life expectancy ≥ 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
  • Adequate organ function and hematologic reserve based on laboratory parameters
  • Have measurable disease defined by RECIST v1.1
  • Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy
  • Tumor indication specific inclusion criteria:
  • Is progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types:; Head and Neck Squamous Cell Carcinoma (HNSCC); Gastric/GEJ Cancer; Biliary Tract Cancer (BTC); Esophageal Squamous Cell Carcinoma (ESCC); Ovarian Cancer; Endometrial Carcinoma; Cervical Cancer; Non-Small Cell Lung Cancer (NSCLC)

Who cannot take part

  • Has not adequately recovered from recent major surgery
  • Has ongoing clinically significant toxicity related to prior therapy
  • Has received prior treatment with an antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload
  • Has malignancies other than disease under study within the past 3 years
  • Has a medical or psychological condition that could interfere with study participation, increase risk, or affect interpretation of the study results
  • Has known sensitivity to any component of CR-002
  • Has active central nervous system (CNS) metastases
  • NOTE: Other protocol defined Inclusion and Exclusion criteria may apply

Where in United States

  • Austin, TexasHospital not named in the registryContact: Crescent Clinical TrialsTaking people
  • Dallas, TexasHospital not named in the registryContact: Crescent Clinical TrialsTaking people
  • Fairfax, VirginiaHospital not named in the registryContact: Crescent Clinical TrialsTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

The 2 groups in the trial

  • CR-002 Dose EscalationTreatment being tested

    Escalating dose levels of CR-002 will be tested to define the maximum tolerated dose of CR-002 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable.

    Treatment: CR-002

  • CR-002 BackfillTreatment being tested

    Escalating dose levels of CR-002 will be tested in indication-specific cohort populations.

    Treatment: CR-002

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Plain-language title
Tests CR-002 in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
2 November 2026